DE69824859D1 - Methoden zur erhöhung der effizienz rekombinanter aav produkte - Google Patents

Methoden zur erhöhung der effizienz rekombinanter aav produkte

Info

Publication number
DE69824859D1
DE69824859D1 DE69824859T DE69824859T DE69824859D1 DE 69824859 D1 DE69824859 D1 DE 69824859D1 DE 69824859 T DE69824859 T DE 69824859T DE 69824859 T DE69824859 T DE 69824859T DE 69824859 D1 DE69824859 D1 DE 69824859D1
Authority
DE
Germany
Prior art keywords
methods
aav
production
expression
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69824859T
Other languages
English (en)
Other versions
DE69824859T2 (de
Inventor
J Samulski
Xiao Xiao
Richard Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Cell Genesys Inc
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
Cell Genesys Inc
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Cell Genesys Inc, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Application granted granted Critical
Publication of DE69824859D1 publication Critical patent/DE69824859D1/de
Publication of DE69824859T2 publication Critical patent/DE69824859T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69824859T 1997-04-14 1998-04-14 Methoden zur erhöhung der effizienz rekombinanter aav produkte Expired - Lifetime DE69824859T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4354797P 1997-04-14 1997-04-14
US43547P 1997-04-14
PCT/US1998/007654 WO1998046728A1 (en) 1997-04-14 1998-04-14 Methods for increasing the efficiency of recombinant aav product

Publications (2)

Publication Number Publication Date
DE69824859D1 true DE69824859D1 (de) 2004-08-05
DE69824859T2 DE69824859T2 (de) 2005-08-04

Family

ID=21927717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824859T Expired - Lifetime DE69824859T2 (de) 1997-04-14 1998-04-14 Methoden zur erhöhung der effizienz rekombinanter aav produkte

Country Status (10)

Country Link
US (2) US6548286B1 (de)
EP (1) EP1007637B1 (de)
JP (2) JP4135120B2 (de)
AT (1) ATE270324T1 (de)
AU (1) AU728220B2 (de)
CA (1) CA2287478C (de)
DE (1) DE69824859T2 (de)
ES (1) ES2224375T3 (de)
NZ (1) NZ500546A (de)
WO (1) WO1998046728A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500546A (en) * 1997-04-14 2001-09-28 Cell Genesys Inc Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
JP2003511037A (ja) * 1999-10-01 2003-03-25 ジェノボ， インコーポレイテッド ＡＡＶｒｅｐ／ｃａｐ遺伝子を含むアデノウイルスを使用する組換えＡＡＶの産生
US7115391B1 (en) * 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2002153278A (ja) * 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2559211A1 (en) 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (monoamine oxidase c)
CA2571159A1 (en) * 2004-06-18 2006-03-30 The University Of Montana Aav mediated gene delivery to cochlear cells
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
EP2484780A1 (de) 2004-07-23 2012-08-08 The University of North Carolina At Chapel Hill Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP2484774A3 (de) 2005-07-21 2012-11-14 Abbott Laboratories Mehrfache Genexpression mit sORF-Konstrukten und Verfahren mit Polyproteinen, Pro-Proteinen und Proteolyse
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
US9868961B2 (en) 2006-03-30 2018-01-16 The Regents Of The University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
EP2007795B1 (de) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav-capsid-proteine
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2007149852A2 (en) 2006-06-19 2007-12-27 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
EP2244740A1 (de) 2008-02-19 2010-11-03 Celladon Corporation Zusammensetzungen zur verbesserten aufnahme von virusvektoren in das myokard
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
US20110150861A1 (en) 2009-10-30 2011-06-23 Abbott Laboratories Sorf constructs and multiple gene expression
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
AU2011238708B2 (en) 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2013116639A1 (en) 2012-02-01 2013-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3567112A1 (de) * 2013-06-13 2019-11-13 Translate Bio, Inc. Virenproduktion auf messenger-rna-basis
US20160251680A1 (en) 2013-11-05 2016-09-01 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2015138357A2 (en) 2014-03-09 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of otc deficency
SG11201607738WA (en) 2014-03-17 2016-10-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
CA2946392A1 (en) 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
EP3194430A1 (de) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-assoziierte virusvektoren zur gentheraüie von stoffwechselkrankheiten
EP3242945B1 (de) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
EP3288594B1 (de) 2015-04-27 2022-06-29 The Trustees of The University of Pennsylvania Duales aav-vektorsystem für crispr-/cas9-vermittelte korrektur von menschlichen erkrankungen
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
EP3325018A4 (de) 2015-07-22 2019-04-24 Duke University Hochdurchsatz-screening von regulatorischen elementfunktionen mit epigenomeditierungstechnologien
CN108368521A (zh) 2015-08-06 2018-08-03 宾夕法尼亚州大学信托人 Glp-1和其在用于治疗代谢疾病的组合物中的用途
ES2929110T3 (es) 2015-08-25 2022-11-24 Univ Duke Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN
EP3344650A4 (de) 2015-08-31 2019-04-17 The Trustees Of The University Of Pennsylvania Aav-epo zur behandlung von haustieren
WO2017053170A1 (en) 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
IL296929A (en) 2015-09-24 2022-12-01 Univ Pennsylvania A preparation and method for the treatment of a complement-mediated disease
WO2017062750A1 (en) 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
WO2017075119A1 (en) 2015-10-28 2017-05-04 The Trustees Of The Univeresity Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
ES2921450T3 (es) 2015-12-11 2022-08-25 Univ Pennsylvania Terapia génica para el tratamiento de la hipercolesterolemia familiar
WO2017106345A1 (en) 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Composition for treatment of crigler-najjar syndrome
RU2762747C2 (ru) 2015-12-14 2021-12-22 Зе Трастис Оф Зе Юниверсити Оф Пенсильвания Генная терапия офтальмологических нарушений
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CA3022600A1 (en) 2016-04-29 2017-11-02 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
EP3481958A4 (de) 2016-07-08 2019-12-25 The Trustees of The University of Pennsylvania Verfahren und zusammensetzungen zur behandlung von störungen und erkrankungen mit rdh12
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
EP3500278B1 (de) 2016-08-19 2024-05-22 University of Florida Research Foundation, Incorporated Zusammensetzungen zur behandlung von erkrankungen mit rekombinantem selbstkomplementärem adeno-assoziiertem virus
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
US20190328846A1 (en) 2016-12-01 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of retinal degenerative diseases
CN110225923A (zh) 2016-12-07 2019-09-10 佛罗里达大学研究基金会有限公司 IL-1Ra cDNA
EP3595688A4 (de) 2017-02-20 2020-12-30 The Trustees Of The University Of Pennsylvania Gentherapie zur behandlung familiärer hypercholesterinämie
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
EP3589738A4 (de) 2017-03-01 2021-01-06 The Trustees of The University of Pennsylvania Gentherapie für augenerkrankungen
CA3054942A1 (en) 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
GB201706090D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Methods for adeno-associated viral vector production
JP2020517238A (ja) 2017-04-18 2020-06-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アデノ随伴ウイルスベクターの産生方法
WO2018200542A1 (en) 2017-04-24 2018-11-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
RU2019139555A (ru) 2017-05-11 2021-06-11 Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания Генная терапия нейрональных цероидных липофусцинозов
AU2018274655A1 (en) 2017-05-24 2019-12-19 Universitat Autonoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence
CA3098592A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
WO2018232149A1 (en) 2017-06-14 2018-12-20 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
KR20230110812A (ko) 2017-10-10 2023-07-25 난트바이오 인코포레이티드 바이러스 생성 페이로드에 대해 독성이 낮은 변형된ec7 세포
US20210071149A1 (en) 2017-12-19 2021-03-11 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
BR112021006060A2 (pt) 2018-10-01 2021-07-20 The Trustees Of The University Of Pennsylvania composições úteis para tratamento de gangliosidose gm1
CA3120923A1 (en) 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
WO2020172490A1 (en) 2019-02-22 2020-08-27 The Trustees Of The University Of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
CN114040980A (zh) 2019-02-26 2022-02-11 宾夕法尼亚州大学信托人 可用于治疗克拉伯病的组合物
CA3140507A1 (en) 2019-05-31 2020-12-03 Universitat Autonoma De Barcelona Insulin gene therapy
US10557149B1 (en) * 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US20220396806A1 (en) 2019-07-26 2022-12-15 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
KR20220112283A (ko) 2019-12-10 2022-08-10 다케다 야쿠힌 고교 가부시키가이샤 Hunter 질환 치료용 아데노-연합된 바이러스 벡터
AR122078A1 (es) 2020-05-13 2022-08-10 Akouos Inc Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4
AU2021281506A1 (en) 2020-05-26 2023-02-02 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
JP2023543125A (ja) 2020-08-24 2023-10-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
CN116887867A (zh) 2020-08-26 2023-10-13 宾夕法尼亚州大学信托人 用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒
CA3197342A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
GB202016254D0 (en) * 2020-10-13 2020-11-25 Freeline Therapeutics Ltd Plasmid system
AR123838A1 (es) 2020-10-18 2023-01-18 Univ Pennsylvania Vector mejorado de virus adenoasociado (aav) y usos de este
WO2022094078A1 (en) 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
WO2022094180A1 (en) 2020-10-29 2022-05-05 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
KR20230117179A (ko) 2020-12-01 2023-08-07 아카우오스, 인크. 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법
EP4271419A1 (de) 2020-12-29 2023-11-08 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von clrn1-assoziiertem hörverlust und/oder sehverlust
CA3206590A1 (en) 2021-01-30 2022-08-04 Maria Fatima Bosch Tubert Gene therapy for monogenic diabetes
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
MX2023009978A (es) 2021-02-26 2023-09-06 Takeda Pharmaceuticals Co Composicion y metodos para el tratamiento de la enfermedad de fabry.
IL307633A (en) 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
EP4326753A2 (de) 2021-04-23 2024-02-28 University of Rochester Genomeditierung durch gerichtete nichthomologe dna-insertion unter verwendung eines retroviralen integrase-cas-fusionsproteins und behandlungsverfahren
EP4089171A1 (de) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Rekombinante tert-codierende virale genome und vektoren
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
TW202325845A (zh) 2021-10-02 2023-07-01 賓州大學委員會 新穎aav衣殼及含其之組成物
TW202340467A (zh) 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
WO2023187728A1 (en) 2022-04-01 2023-10-05 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
WO2023196893A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024042485A1 (en) 2022-08-25 2024-02-29 Takeda Pharmaceutical Company Limited Composition for use in the treatment of fabry disease
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome
WO2024130067A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
CA2176215C (en) * 1993-11-09 2007-06-26 James P. Trempe Stable cell lines capable of expressing the adeno-associated virus replication gene
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
AU715543B2 (en) * 1995-09-08 2000-02-03 Genzyme Corporation Improved AAV vectors for gene therapy
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
NZ500546A (en) * 1997-04-14 2001-09-28 Cell Genesys Inc Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production

Also Published As

Publication number Publication date
JP4249239B2 (ja) 2009-04-02
NZ500546A (en) 2001-09-28
WO1998046728A1 (en) 1998-10-22
CA2287478C (en) 2007-06-19
US6548286B1 (en) 2003-04-15
EP1007637A4 (de) 2002-04-03
ATE270324T1 (de) 2004-07-15
JP4135120B2 (ja) 2008-08-20
US20030211614A1 (en) 2003-11-13
EP1007637A1 (de) 2000-06-14
AU6974198A (en) 1998-11-11
CA2287478A1 (en) 1998-10-22
JP2008043349A (ja) 2008-02-28
AU728220B2 (en) 2001-01-04
JP2001520516A (ja) 2001-10-30
DE69824859T2 (de) 2005-08-04
US7229823B2 (en) 2007-06-12
ES2224375T3 (es) 2005-03-01
EP1007637B1 (de) 2004-06-30

Similar Documents

Publication Publication Date Title
DE69824859D1 (de) Methoden zur erhöhung der effizienz rekombinanter aav produkte
DE69839584D1 (de) Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
Li et al. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy
Ting et al. The nucleotide sequence encoding the hamster 78-kDa glucose-regulated protein (GRP78) and its conservation between hamster and rat
ATE296875T1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
DE69937347D1 (de) Regulierung der hämatopoietischen stammzelldifferenzierung durch verwendung von menschlichen mesenchymalen stammzellen
ATE239796T1 (de) Rekombinanter mva virus und seine verwendung
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
DE69531387D1 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
Guo et al. Chondrogenic effect of precartilaginous stem cells following NLS‐TAT cell penetrating peptide‐assisted transfection of eukaryotic h TGF β3
Cui et al. Human umbilical cord and dental pulp-derived mesenchymal stem cells: Biological characteristics and potential roles in vitro and in vivo
DE69737766D1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
MX2022012279A (es) Variantes de capsides de aav y usos de los mismos.
KR970706397A (ko) IV a2 유전자가 불활성화된 결손 재조합 아데노바이러스(DEFECTIVE RECOMBINANT ADENOVIRUSES WITH AN INACTIVATED IV a2 GENE)
ATE264398T1 (de) Regulierte expression von proteinen in stabil transformierten säugetierzellen
Yang et al. Adeno-associated virus-mediated bone morphogenetic protein-7 gene transfer induces C2C12 cell differentiation into osteoblast lineage cells
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE469920T1 (de) Herstellung von rekombinanten igm in den per.c6 zellen
ES2181684T3 (es) Promotor del gen epidermico humano.
ATA282386A (de) Verfahren zur expression von genen in hefe und dna-fragmente und diese dna-fragmente enthaltende plasmide zur verwendung bei diesem verfahren
Pruchnic et al. Muscle derived cell mediated ex vivo gene transfer to the lower urinary tract: comparison of viral vectors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition